



## Clinical trial results:

### A 26-Week Extension Study of the Safety and Clinical Effects of EVP-6124 in Subjects with Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication

#### Summary

EudraCT number	2013-002654-75
Trial protocol	DE BE GB ES IT NL CZ
Global end of trial date	23 December 2015

#### Results information

Result version number	v1 (current)
This version publication date	05 February 2017
First version publication date	05 February 2017

#### Trial information

##### Trial identification

Sponsor protocol code	EVP-6124-026
-----------------------	--------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-
Other trial identifiers	IND Number: 102623

Notes:

#### Sponsors

Sponsor organisation name	FORUM Pharmaceuticals Inc.
Sponsor organisation address	225 Second Avenue, Waltham, MA, United States, 02451
Public contact	Franz Buchholzer, inVentiv Health Clinical UK Ltd, Regopseurope@inventivhealth.com
Scientific contact	Franz Buchholzer, inVentiv Health Clinical UK Ltd, Regopseurope@inventivhealth.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	14 June 2016
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	23 December 2015
Was the trial ended prematurely?	Yes

Notes:

## General information about the trial

Main objective of the trial:

To assess the safety of 2 fixed doses of EVP-6124 (2 or 3 mg daily) for up to 52 weeks in subjects with Alzheimer's disease (AD) who complete (Day 182) studies EVP-6124-024 or EVP-6124-025

Protection of trial subjects:

There were no invasive or potentially pain-inducing procedures in this study except blood sampling. If patients experience pain, analgesic treatment was allowed per the physician discretion.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	05 June 2014
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Spain: 6
Country: Number of subjects enrolled	Netherlands: 8
Country: Number of subjects enrolled	Poland: 11
Country: Number of subjects enrolled	United Kingdom: 5
Country: Number of subjects enrolled	Belgium: 4
Country: Number of subjects enrolled	Czech Republic: 8
Country: Number of subjects enrolled	France: 5
Country: Number of subjects enrolled	Italy: 5
Country: Number of subjects enrolled	Australia: 6
Country: Number of subjects enrolled	Canada: 14
Country: Number of subjects enrolled	Japan: 7
Country: Number of subjects enrolled	South Africa: 43
Country: Number of subjects enrolled	Korea, Republic of: 22
Country: Number of subjects enrolled	United States: 204
Worldwide total number of subjects	348
EEA total number of subjects	52

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	60
From 65 to 84 years	274
85 years and over	14

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

In this extension study, subjects who complete study EVP-6124-024 or EVP-6124-025 (Day 182) and fulfill all entry criteria will be randomized. Assessments performed at the final double-blind study visit (Day 182) will serve as the baseline for this extension study for all subjects.

### Period 1

Period 1 title	Double-blind period (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Carer

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	EVP-6124, 2 mg

Arm description:

Previously treated with EVP-6124 will receive the same dose during this study as received in the previous study and subjects previously treated with placebo will be randomized to EVP-6124 2 or 3 mg daily (1:1 ratio).

Arm type	Experimental
Investigational medicinal product name	Encenicline
Investigational medicinal product code	EVP-6124
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects will be instructed to take 1 tablet once daily at the same time each day, preferably between 8 and 10 AM, with or without food, and with an adequate amount of water.

<b>Arm title</b>	EVP-6124, 3 mg
------------------	----------------

Arm description:

Previously treated with EVP-6124 will receive the same dose during this study as received in the previous study and subjects previously treated with placebo will be randomized to EVP-6124 2 or 3 mg daily (1:1 ratio).

Arm type	Experimental
Investigational medicinal product name	Encenicline
Investigational medicinal product code	EVP-6124
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects will be instructed to take 1 tablet once daily at the same time each day, preferably between 8 and 10 AM, with or without food, and with an adequate amount of water.

<b>Arm title</b>	Pbo-EVP-6124, 2 mg
------------------	--------------------

Arm description:

Previously treated with EVP-6124 will receive the same dose during this study as received in the previous study and subjects previously treated with placebo will be randomized to EVP-6124 2 or 3 mg daily (1:1 ratio).

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Encenicline
Investigational medicinal product code	EVP-6124
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

**Dosage and administration details:**

Subjects will be instructed to take 1 tablet once daily at the same time each day, preferably between 8 and 10 AM, with or without food, and with an adequate amount of water.

<b>Arm title</b>	Pbo-EVP-6124, 3 mg
------------------	--------------------

**Arm description:**

Previously treated with EVP-6124 will receive the same dose during this study as received in the previous study and subjects previously treated with placebo will be randomized to EVP-6124 2 or 3 mg daily (1:1 ratio).

Arm type	Experimental
Investigational medicinal product name	Encenicline
Investigational medicinal product code	EVP-6124
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

**Dosage and administration details:**

Subjects will be instructed to take 1 tablet once daily at the same time each day, preferably between 8 and 10 AM, with or without food, and with an adequate amount of water.

<b>Number of subjects in period 1</b>	EVP-6124, 2 mg	EVP-6124, 3 mg	Pbo-EVP-6124, 2 mg
Started	111	114	61
Completed	37	36	20
Not completed	74	78	41
Consent withdrawn by subject	2	1	1
Adverse event, non-fatal	5	5	4
Other	3	2	5
Withdrawal by Subject/Caregiver	2	2	-
Due to Clinical hold	60	67	31
Lost to follow-up	2	1	-

<b>Number of subjects in period 1</b>	Pbo-EVP-6124, 3 mg
Started	62
Completed	12
Not completed	50
Consent withdrawn by subject	3
Adverse event, non-fatal	3
Other	3
Withdrawal by Subject/Caregiver	2
Due to Clinical hold	39
Lost to follow-up	-



## Baseline characteristics

### Reporting groups

Reporting group title	EVP-6124, 2 mg
-----------------------	----------------

Reporting group description:

Previously treated with EVP-6124 will receive the same dose during this study as received in the previous study and subjects previously treated with placebo will be randomized to EVP-6124 2 or 3 mg daily (1:1 ratio).

Reporting group title	EVP-6124, 3 mg
-----------------------	----------------

Reporting group description:

Previously treated with EVP-6124 will receive the same dose during this study as received in the previous study and subjects previously treated with placebo will be randomized to EVP-6124 2 or 3 mg daily (1:1 ratio).

Reporting group title	Pbo-EVP-6124, 2 mg
-----------------------	--------------------

Reporting group description:

Previously treated with EVP-6124 will receive the same dose during this study as received in the previous study and subjects previously treated with placebo will be randomized to EVP-6124 2 or 3 mg daily (1:1 ratio).

Reporting group title	Pbo-EVP-6124, 3 mg
-----------------------	--------------------

Reporting group description:

Previously treated with EVP-6124 will receive the same dose during this study as received in the previous study and subjects previously treated with placebo will be randomized to EVP-6124 2 or 3 mg daily (1:1 ratio).

Reporting group values	EVP-6124, 2 mg	EVP-6124, 3 mg	Pbo-EVP-6124, 2 mg
Number of subjects	111	114	61
Age categorical Units: Subjects			
Adults (18-64 years)	21	26	7
From 65-84 years	85	86	51
85 years and over	5	2	3
Age continuous Units: years			
arithmetic mean	72.8	71.7	74.3
full range (min-max)	57 to 85	55 to 85	55 to 85
Gender categorical Units: Subjects			
Female	49	62	40
Male	62	52	21

Reporting group values	Pbo-EVP-6124, 3 mg	Total	
Number of subjects	62	348	
Age categorical Units: Subjects			
Adults (18-64 years)	6	60	
From 65-84 years	52	274	
85 years and over	4	14	
Age continuous Units: years			
arithmetic mean	75.4		
full range (min-max)	57 to 85	-	

Gender categorical			
Units: Subjects			
Female	37	188	
Male	25	160	



## End points

### End points reporting groups

Reporting group title	EVP-6124, 2 mg
Reporting group description: Previously treated with EVP-6124 will receive the same dose during this study as received in the previous study and subjects previously treated with placebo will be randomized to EVP-6124 2 or 3 mg daily (1:1 ratio).	
Reporting group title	EVP-6124, 3 mg
Reporting group description: Previously treated with EVP-6124 will receive the same dose during this study as received in the previous study and subjects previously treated with placebo will be randomized to EVP-6124 2 or 3 mg daily (1:1 ratio).	
Reporting group title	Pbo-EVP-6124, 2 mg
Reporting group description: Previously treated with EVP-6124 will receive the same dose during this study as received in the previous study and subjects previously treated with placebo will be randomized to EVP-6124 2 or 3 mg daily (1:1 ratio).	
Reporting group title	Pbo-EVP-6124, 3 mg
Reporting group description: Previously treated with EVP-6124 will receive the same dose during this study as received in the previous study and subjects previously treated with placebo will be randomized to EVP-6124 2 or 3 mg daily (1:1 ratio).	

### Primary: Albumin (Change from baseline)

End point title	Albumin (Change from baseline) <sup>[1]</sup>
End point description:	
End point type	Primary
End point timeframe: Days 28, 56, 84, 112, 140, and 182. Performed non-fasting at each clinic visit.	
Notes: [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Due to the premature termination of the studies, a full statistical analysis could not be performed.	

End point values	EVP-6124, 2 mg	EVP-6124, 3 mg	Pbo-EVP-6124, 2 mg	Pbo-EVP-6124, 3 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	106	110	61	59
Units: (g/L)				
arithmetic mean (full range (min-max))	-1 (-7 to 2)	-0.7 (-7 to 3)	-0.3 (-6 to 6)	-1.2 (-6 to 3)

### Statistical analyses

No statistical analyses for this end point

### Primary: Alkaline Phosphatase (Change from baseline)

End point title	Alkaline Phosphatase (Change from baseline) <sup>[2]</sup>			
End point description:				
End point type	Primary			
End point timeframe:				
Days 28, 56, 84, 112, 140, and 182. Performed non-fasting at each clinic visit.				
Notes:				
[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.				
Justification: Due to the premature termination of the studies, a full statistical analysis could not be performed.				
End point values	EVP-6124, 2 mg	EVP-6124, 3 mg	Pbo-EVP-6124, 2 mg	Pbo-EVP-6124, 3 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	106	110	61	59
Units: U/L				
arithmetic mean (full range (min-max))	-1.1 (-29 to 12)	2.6 (-25 to 29)	-2.9 (-31 to 19)	9.1 (-15 to 104)

## Statistical analyses

No statistical analyses for this end point

## Primary: Alanine Aminotransferase (Change from baseline)

End point title	Alanine Aminotransferase (Change from baseline) <sup>[3]</sup>			
End point description:				
End point type	Primary			
End point timeframe:				
Days 28, 56, 84, 112, 140, and 182. Performed non-fasting at each clinic visit.				
Notes:				
[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.				
Justification: Due to the premature termination of the studies, a full statistical analysis could not be performed.				
End point values	EVP-6124, 2 mg	EVP-6124, 3 mg	Pbo-EVP-6124, 2 mg	Pbo-EVP-6124, 3 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	106	110	61	59
Units: U/L				
arithmetic mean (full range (min-max))	-2.5 (-18 to 7)	-1.7 (-17 to 16)	1.2 (-7 to 12)	0.2 (-5 to 17)

## Statistical analyses

No statistical analyses for this end point

**Primary: Aspartate Aminotransferase (Change from baseline)**

End point title	Aspartate Aminotransferase (Change from baseline) <sup>[4]</sup>
-----------------	--

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Days 28, 56, 84, 112, 140, and 182. Performed non-fasting at each clinic visit.

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due to the premature termination of the studies, a full statistical analysis could not be performed.

End point values	EVP-6124, 2 mg	EVP-6124, 3 mg	Pbo-EVP-6124, 2 mg	Pbo-EVP-6124, 3 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	106	110	61	59
Units: U/L				
arithmetic mean (full range (min-max))	-2.9 (-35 to 3)	-1.7 (-18 to 10)	0.7 (-5 to 8)	0 (-15 to 10)

**Statistical analyses**

No statistical analyses for this end point

**Primary: Bicarbonate (Change from baseline)**

End point title	Bicarbonate (Change from baseline) <sup>[5]</sup>
-----------------	---

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Days 28, 56, 84, 112, 140, and 182. Performed non-fasting at each clinic visit.

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due to the premature termination of the studies, a full statistical analysis could not be performed.

End point values	EVP-6124, 2 mg	EVP-6124, 3 mg	Pbo-EVP-6124, 2 mg	Pbo-EVP-6124, 3 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	106	110	61	59
Units: mmol/L				
arithmetic mean (full range (min-max))	-0.75 (-5.7 to 3.6)	-0.22 (-8.1 to 8.2)	0.29 (-4.4 to 5.2)	0.59 (-2.4 to 7.9)

**Statistical analyses**

No statistical analyses for this end point

**Primary: Bilirubin (Change from baseline)**

End point title	Bilirubin (Change from baseline) <sup>[6]</sup>
-----------------	---

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Days 28, 56, 84, 112, 140, and 182. Performed non-fasting at each clinic visit.

Notes:

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due to the premature termination of the studies, a full statistical analysis could not be performed.

End point values	EVP-6124, 2 mg	EVP-6124, 3 mg	Pbo-EVP-6124, 2 mg	Pbo-EVP-6124, 3 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	106	110	61	59
Units: umol/L				
arithmetic mean (full range (min-max))	0.77 (-3.9 to 9.4)	0 (-8 to 7.1)	-0.07 (-6.9 to 8)	0.03 (-3.4 to 4.4)

**Statistical analyses**

No statistical analyses for this end point

**Primary: Blood Urea Nitrogen (Change from baseline)**

End point title	Blood Urea Nitrogen (Change from baseline) <sup>[7]</sup>
-----------------	---

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Days 28, 56, 84, 112, 140, and 182. Performed non-fasting at each clinic visit.

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due to the premature termination of the studies, a full statistical analysis could not be performed.

End point values	EVP-6124, 2 mg	EVP-6124, 3 mg	Pbo-EVP-6124, 2 mg	Pbo-EVP-6124, 3 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	106	110	61	59
Units: MMOL UREA/L				
arithmetic mean (full range (min-max))	-0.29 (-5 to 2.5)	-0.09 (-4.7 to 2.1)	-0.31 (-5 to 2.5)	0.38 (-5.4 to 5.4)

**Statistical analyses**

No statistical analyses for this end point

**Primary: Calcium (Change from baseline)**

End point title	Calcium (Change from baseline) <sup>[8]</sup>
-----------------	---

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Days 28, 56, 84, 112, 140, and 182. Performed non-fasting at each clinic visit.

Notes:

[8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due to the premature termination of the studies, a full statistical analysis could not be performed.

End point values	EVP-6124, 2 mg	EVP-6124, 3 mg	Pbo-EVP-6124, 2 mg	Pbo-EVP-6124, 3 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	106	110	61	59
Units: mmol/L				
arithmetic mean (full range (min-max))	-0.024 (-0.22 to 0.16)	-0.023 (-0.28 to 0.13)	0.006 (-0.15 to 0.16)	-0.028 (-0.23 to 0.14)

**Statistical analyses**

No statistical analyses for this end point

**Primary: Creatine Kinase (Change from baseline)**

End point title	Creatine Kinase (Change from baseline) <sup>[9]</sup>
-----------------	---

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Days 28, 56, 84, 112, 140, and 182. Performed non-fasting at each clinic visit.

Notes:

[9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due to the premature termination of the studies, a full statistical analysis could not be performed.

End point values	EVP-6124, 2 mg	EVP-6124, 3 mg	Pbo-EVP-6124, 2 mg	Pbo-EVP-6124, 3 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	106	110	61	59
Units: U/L				
arithmetic mean (full range (min-max))	-26.8 (-344 to 61)	-11.6 (-210 to 106)	10.2 (-36 to 123)	-4.6 (-142 to 257)

**Statistical analyses**

No statistical analyses for this end point

**Primary: Chloride (Change from baseline)**

End point title	Chloride (Change from baseline) <sup>[10]</sup>
-----------------	---

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Days 28, 56, 84, 112, 140, and 182. Performed non-fasting at each clinic visit.

Notes:

[10] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due to the premature termination of the studies, a full statistical analysis could not be performed.

End point values	EVP-6124, 2 mg	EVP-6124, 3 mg	Pbo-EVP-6124, 2 mg	Pbo-EVP-6124, 3 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	106	110	61	59
Units: mmol/L				
arithmetic mean (full range (min-max))	0.5 (-5 to 6)	-0.2 (-5 to 6)	0.5 (-6 to 8)	-0.4 (-12 to 6)

**Statistical analyses**

No statistical analyses for this end point

**Primary: Creatinine (Change from baseline)**

End point title	Creatinine (Change from baseline) <sup>[11]</sup>
-----------------	---

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Days 28, 56, 84, 112, 140, and 182. Performed non-fasting at each clinic visit.

Notes:

[11] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due to the premature termination of the studies, a full statistical analysis could not be performed.

End point values	EVP-6124, 2 mg	EVP-6124, 3 mg	Pbo-EVP-6124, 2 mg	Pbo-EVP-6124, 3 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	106	110	61	59
Units: umol/L				
arithmetic mean (full range (min-max))	2.51 (-15.9 to 19.5)	2.08 (-15.9 to 23.9)	2.98 (-124.6 to 41.5)	0.52 (-23.9 to 31.8)

**Statistical analyses**

No statistical analyses for this end point

**Primary: Gamma Glutamyl Transferase (Change from baseline)**

End point title	Gamma Glutamyl Transferase (Change from baseline) <sup>[12]</sup>
-----------------	---

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Days 28, 56, 84, 112, 140, and 182. Performed non-fasting at each clinic visit.

Notes:

[12] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due to the premature termination of the studies, a full statistical analysis could not be performed.

End point values	EVP-6124, 2 mg	EVP-6124, 3 mg	Pbo-EVP-6124, 2 mg	Pbo-EVP-6124, 3 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	106	110	61	59
Units: U/L				
arithmetic mean (full range (min-max))	-0.7 (-14 to 12)	0.9 (-17 to 24)	1 (-4 to 11)	8.6 (-12 to 129)

**Statistical analyses**

No statistical analyses for this end point

**Primary: Glucose (Change from baseline)**

End point title	Glucose (Change from baseline) <sup>[13]</sup>
-----------------	--

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Days 28, 56, 84, 112, 140, and 182. Performed non-fasting at each clinic visit.

Notes:

[13] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due to the premature termination of the studies, a full statistical analysis could not be performed.

End point values	EVP-6124, 2 mg	EVP-6124, 3 mg	Pbo-EVP-6124, 2 mg	Pbo-EVP-6124, 3 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	106	110	61	59
Units: mmol/L				
arithmetic mean (full range (min-max))	-0.27 (-9.04 to 2.94)	0.408 (-5.94 to 13.77)	0.309 (-1.5 to 3.44)	-0.382 (-4.11 to 4.49)

**Statistical analyses**

No statistical analyses for this end point

**Primary: Potassium (Change from baseline)**

End point title	Potassium (Change from baseline) <sup>[14]</sup>
-----------------	--

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Days 28, 56, 84, 112, 140, and 182. Performed non-fasting at each clinic visit.

Notes:

[14] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due to the premature termination of the studies, a full statistical analysis could not be performed.

End point values	EVP-6124, 2 mg	EVP-6124, 3 mg	Pbo-EVP-6124, 2 mg	Pbo-EVP-6124, 3 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	106	110	61	59
Units: mmol/L				
arithmetic mean (full range (min-max))	0.06 (-1.6 to 1.1)	-0.07 (-0.8 to 1)	0.16 (-0.5 to 1.6)	0.15 (-0.7 to 0.9)

**Statistical analyses**

No statistical analyses for this end point

**Primary: Magnesium (Change from baseline)**

End point title	Magnesium (Change from baseline) <sup>[15]</sup>
-----------------	--

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Days 28, 56, 84, 112, 140, and 182. Performed non-fasting at each clinic visit.

Notes:

[15] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due to the premature termination of the studies, a full statistical analysis could not be performed.

End point values	EVP-6124, 2 mg	EVP-6124, 3 mg	Pbo-EVP-6124, 2 mg	Pbo-EVP-6124, 3 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	106	110	61	59
Units: mmol/L				
arithmetic mean (full range (min-max))	-0.0079 (-0.123 to 0.164)	-0.0253 (-0.124 to 0.083)	-0.0057 (-0.214 to 0.205)	-0.0213 (-0.164 to 0.185)

**Statistical analyses**



No statistical analyses for this end point

### Primary: Inorganic Phosphate (Change from baseline)

End point title Inorganic Phosphate (Change from baseline)<sup>[16]</sup>

End point description:

End point type Primary

End point timeframe:

Days 28, 56, 84, 112, 140, and 182. Performed non-fasting at each clinic visit.

Notes:

[16] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due to the premature termination of the studies, a full statistical analysis could not be performed.

End point values	EVP-6124, 2 mg	EVP-6124, 3 mg	Pbo-EVP-6124, 2 mg	Pbo-EVP-6124, 3 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	106	110	61	59
Units: mmol/L				
arithmetic mean (full range (min-max))	-0.0291 (-0.394 to 0.339)	-0.017 (-0.419 to 0.368)	0.0025 (-0.362 to 0.649)	0.0199 (-0.294 to 0.62)

### Statistical analyses

No statistical analyses for this end point

### Primary: Protein (Change from baseline)

End point title Protein (Change from baseline)<sup>[17]</sup>

End point description:

End point type Primary

End point timeframe:

Days 28, 56, 84, 112, 140, and 182. Performed non-fasting at each clinic visit.

Notes:

[17] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due to the premature termination of the studies, a full statistical analysis could not be performed.

End point values	EVP-6124, 2 mg	EVP-6124, 3 mg	Pbo-EVP-6124, 2 mg	Pbo-EVP-6124, 3 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	106	110	61	59
Units: g/L				
arithmetic mean (full range (min-max))	-1.5 (-12 to 4)	-0.9 (-10 to 6)	-0.4 (-6 to 6)	-0.2 (-5 to 8)

## Statistical analyses

No statistical analyses for this end point

### Primary: Sodium (Change from baseline)

End point title Sodium (Change from baseline)<sup>[18]</sup>

End point description:

End point type Primary

End point timeframe:

Days 28, 56, 84, 112, 140, and 182. Performed non-fasting at each clinic visit.

Notes:

[18] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due to the premature termination of the studies, a full statistical analysis could not be performed.

End point values	EVP-6124, 2 mg	EVP-6124, 3 mg	Pbo-EVP-6124, 2 mg	Pbo-EVP-6124, 3 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	106	110	61	59
Units: mmol/L				
arithmetic mean (full range (min-max))	0.8 (-4 to 8)	0.1 (-8 to 5)	1 (-4 to 6)	0.2 (-11 to 9)

## Statistical analyses

No statistical analyses for this end point

### Primary: Urate (Change from baseline)

End point title Urate (Change from baseline)<sup>[19]</sup>

End point description:

End point type Primary

End point timeframe:

Days 28, 56, 84, 112, 140, and 182. Performed non-fasting at each clinic visit.

Notes:

[19] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due to the premature termination of the studies, a full statistical analysis could not be performed.

End point values	EVP-6124, 2 mg	EVP-6124, 3 mg	Pbo-EVP-6124, 2 mg	Pbo-EVP-6124, 3 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	106	110	61	59
Units: mmol/L				
arithmetic mean (full range (min-max))	-0.004 (-0.12 to 0.13)	0 (-0.08 to 0.1)	0.008 (-0.08 to 0.12)	0.014 (-0.1 to 0.1)

## Statistical analyses

No statistical analyses for this end point

### Primary: Leukocytes (Change from baseline)

End point title Leukocytes (Change from baseline)<sup>[20]</sup>

End point description:

End point type Primary

End point timeframe:

Days 28, 56, 84, 112, 140, and 182. Performed non-fasting at each clinic visit.

Notes:

[20] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due to the premature termination of the studies, a full statistical analysis could not be performed.

End point values	EVP-6124, 2 mg	EVP-6124, 3 mg	Pbo-EVP-6124, 2 mg	Pbo-EVP-6124, 3 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	106	110	61	59
Units: 10 <sup>9</sup> /L				
arithmetic mean (full range (min-max))	0.016 (-2.28 to 8.25)	-0.219 (-3.58 to 1.74)	-0.245 (-5.27 to 2.66)	-0.013 (-10.64 to 4.29)

## Statistical analyses

No statistical analyses for this end point

### Primary: Erythrocytes (Change from baseline)

End point title Erythrocytes (Change from baseline)<sup>[21]</sup>

End point description:

End point type Primary

End point timeframe:

Days 28, 56, 84, 112, 140, and 182. Performed non-fasting at each clinic visit.

Notes:

[21] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due to the premature termination of the studies, a full statistical analysis could not be performed.

End point values	EVP-6124, 2 mg	EVP-6124, 3 mg	Pbo-EVP-6124, 2 mg	Pbo-EVP-6124, 3 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	106	110	61	59
Units: 10 <sup>12</sup> /L				
arithmetic mean (full range (min-max))	-0.054 (-0.63 to 0.75)	-0.085 (-0.65 to 0.42)	-0.065 (-1.74 to 0.45)	-0.075 (-0.51 to 0.55)

## Statistical analyses

No statistical analyses for this end point

### Primary: Hemoglobin (Change from baseline)

End point title Hemoglobin (Change from baseline)<sup>[22]</sup>

End point description:

End point type Primary

End point timeframe:

Days 28, 56, 84, 112, 140, and 182. Performed non-fasting at each clinic visit.

Notes:

[22] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due to the premature termination of the studies, a full statistical analysis could not be performed.

End point values	EVP-6124, 2 mg	EVP-6124, 3 mg	Pbo-EVP-6124, 2 mg	Pbo-EVP-6124, 3 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	106	110	61	59
Units: g/L				
arithmetic mean (full range (min-max))	-2.1 (-35 to 13)	-1.7 (-20 to 11)	-1.1 (-42 to 23)	-2.7 (-21 to 11)

## Statistical analyses

No statistical analyses for this end point

### Primary: Hematocrit (change from baseline)

End point title Hematocrit (change from baseline)<sup>[23]</sup>

End point description:

End point type Primary

End point timeframe:

Days 28, 56, 84, 112, 140, and 182. Performed non-fasting at each clinic visit.

Notes:

[23] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due to the premature termination of the studies, a full statistical analysis could not be performed.

End point values	EVP-6124, 2 mg	EVP-6124, 3 mg	Pbo-EVP-6124, 2 mg	Pbo-EVP-6124, 3 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	106	110	61	59
Units: %(v/v)				
arithmetic mean (full range (min-max))	0.004 (-0.091 to 0.074)	-0.0038 (-0.058 to 0.061)	0.0006 (-0.144 to 0.059)	-0.0023 (-0.073 to 0.049)

## Statistical analyses

No statistical analyses for this end point

### Primary: Platelets (Change from baseline)

End point title Platelets (Change from baseline)<sup>[24]</sup>

End point description:

End point type Primary

End point timeframe:

Days 28, 56, 84, 112, 140, and 182. Performed non-fasting at each clinic visit.

Notes:

[24] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due to the premature termination of the studies, a full statistical analysis could not be performed.

End point values	EVP-6124, 2 mg	EVP-6124, 3 mg	Pbo-EVP-6124, 2 mg	Pbo-EVP-6124, 3 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	106	110	61	59
Units: 10 <sup>9</sup> /L				
arithmetic mean (full range (min-max))	-13.1 (-84 to 47)	-6.3 (-65 to 135)	2.7 (-71 to 236)	9.7 (-141 to 329)

## Statistical analyses

No statistical analyses for this end point

### Primary: Basophils (Change from baseline)

End point title Basophils (Change from baseline)<sup>[25]</sup>

End point description:

End point type Primary

End point timeframe:

Days 28, 56, 84, 112, 140, and 182. Performed non-fasting at each clinic visit.

Notes:

[25] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due to the premature termination of the studies, a full statistical analysis could not be performed.

End point values	EVP-6124, 2 mg	EVP-6124, 3 mg	Pbo-EVP-6124, 2 mg	Pbo-EVP-6124, 3 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	106	110	61	59
Units: 10 <sup>9</sup> /L				
arithmetic mean (full range (min-max))	-0.001 (-0.06 to 0.05)	0 (-0.03 to 0.08)	0.003 (-0.11 to 0.11)	0.001 (-0.02 to 0.03)

## Statistical analyses

No statistical analyses for this end point

### Primary: Eosinophils (Change from baseline)

End point title	Eosinophils (Change from baseline) <sup>[26]</sup>
-----------------	--

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Days 28, 56, 84, 112, 140, and 182. Performed non-fasting at each clinic visit.

Notes:

[26] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due to the premature termination of the studies, a full statistical analysis could not be performed.

End point values	EVP-6124, 2 mg	EVP-6124, 3 mg	Pbo-EVP-6124, 2 mg	Pbo-EVP-6124, 3 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	106	110	61	59
Units: 10 <sup>9</sup> /L				
arithmetic mean (full range (min-max))	-0.01 (-0.31 to 0.25)	-0.017 (-0.6 to 0.28)	-0.009 (-0.38 to 0.32)	0.04 (-0.15 to 0.44)

## Statistical analyses

No statistical analyses for this end point

### Primary: Lymphocytes (Change from baseline)

End point title	Lymphocytes (Change from baseline) <sup>[27]</sup>
-----------------	--

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Days 28, 56, 84, 112, 140, and 182. Performed non-fasting at each clinic visit.

Notes:

[27] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due to the premature termination of the studies, a full statistical analysis could not be performed.

End point values	EVP-6124, 2 mg	EVP-6124, 3 mg	Pbo-EVP-6124, 2 mg	Pbo-EVP-6124, 3 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	106	110	61	59
Units: 10 <sup>9</sup> /L				
arithmetic mean (full range (min-max))	2.116 (0.64 to 19.97)	1.725 (0.58 to 3.97)	2.364 (0.81 to 19.09)	1.502 (0.7 to 3.33)

## Statistical analyses

No statistical analyses for this end point

### Primary: Monocytes (Change from baseline)

End point title	Monocytes (Change from baseline) <sup>[28]</sup>
-----------------	--

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Days 28, 56, 84, 112, 140, and 182. Performed non-fasting at each clinic visit.

Notes:

[28] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due to the premature termination of the studies, a full statistical analysis could not be performed.

End point values	EVP-6124, 2 mg	EVP-6124, 3 mg	Pbo-EVP-6124, 2 mg	Pbo-EVP-6124, 3 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	106	110	61	59
Units: 10 <sup>9</sup> /L				
arithmetic mean (full range (min-max))	-0.006 (-0.39 to 0.45)	-0.002 (-0.64 to 1.03)	-0.002 (-0.62 to 0.76)	0.034 (-0.59 to 0.5)

## Statistical analyses

No statistical analyses for this end point

### Primary: Neutrophils (Change from baseline)

End point title	Neutrophils (Change from baseline) <sup>[29]</sup>
-----------------	--

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Days 28, 56, 84, 112, 140, and 182. Performed non-fasting at each clinic visit.

Notes:

[29] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due to the premature termination of the studies, a full statistical analysis could not be performed.

End point values	EVP-6124, 2 mg	EVP-6124, 3 mg	Pbo-EVP-6124, 2 mg	Pbo-EVP-6124, 3 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	106	110	61	59
Units: 10 <sup>9</sup> /L				
arithmetic mean (full range (min-max))	0.011 (-2.05 to 5.16)	-0.012 (-3.07 to 2.3)	-0.418 (-5.57 to 2.47)	-0.015 (-9.83 to 3.26)

### Statistical analyses

No statistical analyses for this end point

### Primary: Urinalysis - pH

End point title	Urinalysis - pH <sup>[30]</sup>
-----------------	---------------------------------

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Days 28, 56, 84, 112, 140, and 182. Performed non-fasting at each clinic visit.

Notes:

[30] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due to the premature termination of the studies, a full statistical analysis could not be performed.

End point values	EVP-6124, 2 mg	EVP-6124, 3 mg	Pbo-EVP-6124, 2 mg	Pbo-EVP-6124, 3 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	106	110	61	59
Units: N/A				
arithmetic mean (full range (min-max))	-0.1 (-3 to 2)	-0.5 (-3 to 1)	0.1 (-2 to 2)	-0.3 (-3 to 1)

### Statistical analyses

No statistical analyses for this end point

### Primary: Urinalysis - Specific Gravity

End point title	Urinalysis - Specific Gravity <sup>[31]</sup>
-----------------	---

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Days 28, 56, 84, 112, 140, and 182. Performed non-fasting at each clinic visit.

Notes:

[31] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due to the premature termination of the studies, a full statistical analysis could not be performed.



End point values	EVP-6124, 2 mg	EVP-6124, 3 mg	Pbo-EVP-6124, 2 mg	Pbo-EVP-6124, 3 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	106	110	61	59
Units: N/A				
arithmetic mean (full range (min-max))	0.001 (-0.025 to 0.02)	0.0019 (-0.02 to 0.025)	0 (-0.02 to 0.015)	0 (-0.015 to 0.01)

## Statistical analyses

No statistical analyses for this end point

### Primary: Heart Rate (Change from baseline)

End point title	Heart Rate (Change from baseline) <sup>[32]</sup>
-----------------	---

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Days 28, 56, 84, 112, 140, and 182

Notes:

[32] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due to the premature termination of the studies, a full statistical analysis could not be performed.

End point values	EVP-6124, 2 mg	EVP-6124, 3 mg	Pbo-EVP-6124, 2 mg	Pbo-EVP-6124, 3 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	106	110	61	59
Units: beats/min				
arithmetic mean (full range (min-max))	1.5 (-22 to 26)	2.5 (-17 to 27)	-0.6 (-40 to 13)	2.5 (-19 to 19)

## Statistical analyses

No statistical analyses for this end point

### Primary: QT Duration (Change from baseline)

End point title	QT Duration (Change from baseline) <sup>[33]</sup>
-----------------	--

End point description:

End point type	Primary
----------------	---------

End point timeframe:

12-lead electrocardiogram (ECG): Days 28, 56, 112, 140, and 182

Notes:

[33] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due to the premature termination of the studies, a full statistical analysis could not be performed.

End point values	EVP-6124, 2 mg	EVP-6124, 3 mg	Pbo-EVP-6124, 2 mg	Pbo-EVP-6124, 3 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	106	110	61	59
Units: msec				
arithmetic mean (full range (min-max))	-6 (-50 to 52)	-4.9 (-86 to 42)	-1.8 (-40 to 126)	-7.3 (-64 to 38)

## Statistical analyses

No statistical analyses for this end point

### Primary: QRS Duration (Change from baseline)

End point title	QRS Duration (Change from baseline) <sup>[34]</sup>
-----------------	---

End point description:

End point type	Primary
----------------	---------

End point timeframe:

12-lead electrocardiogram (ECG): Days 28, 56, 112, 140, and 182

Notes:

[34] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due to the premature termination of the studies, a full statistical analysis could not be performed.

End point values	EVP-6124, 2 mg	EVP-6124, 3 mg	Pbo-EVP-6124, 2 mg	Pbo-EVP-6124, 3 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	106	110	61	59
Units: msec				
arithmetic mean (full range (min-max))	-1.8 (-12 to 8)	0.5 (-14 to 46)	1.2 (-12 to 14)	-0.7 (-12 to 6)

## Statistical analyses

No statistical analyses for this end point

### Primary: PR Duration (Change from baseline)

End point title	PR Duration (Change from baseline) <sup>[35]</sup>
-----------------	--

End point description:

End point type	Primary
----------------	---------

End point timeframe:

12-lead electrocardiogram (ECG): Days 28, 56, 112, 140, and 182

Notes:

[35] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due to the premature termination of the studies, a full statistical analysis could not be performed.

End point values	EVP-6124, 2 mg	EVP-6124, 3 mg	Pbo-EVP-6124, 2 mg	Pbo-EVP-6124, 3 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	106	110	61	59
Units: msec				
arithmetic mean (full range (min-max))	2 (-22 to 24)	2 (-50 to 44)	0.3 (-28 to 24)	-3 (-30 to 18)

## Statistical analyses

No statistical analyses for this end point

### Primary: QTcF - Fridericia's Correction Formula (Change from baseline)

End point title	QTcF - Fridericia's Correction Formula (Change from
-----------------	---

End point description:

End point type	Primary
----------------	---------

End point timeframe:

12-lead electrocardiogram (ECG): Days 28, 56, 112, 140, and 182

Notes:

[36] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due to the premature termination of the studies, a full statistical analysis could not be performed.

End point values	EVP-6124, 2 mg	EVP-6124, 3 mg	Pbo-EVP-6124, 2 mg	Pbo-EVP-6124, 3 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	106	110	61	59
Units: msec				
arithmetic mean (full range (min-max))	-2.9 (-37 to 23)	0.7 (-25 to 29)	-4.4 (-30 to 31)	-1.5 (-34 to 58)

## Statistical analyses

No statistical analyses for this end point

### Primary: Temperature (Change from baseline)

End point title	Temperature (Change from baseline) <sup>[37]</sup>
-----------------	--

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Days 28, 56, 84, 112, 140, and 182

Notes:

[37] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due to the premature termination of the studies, a full statistical analysis could not be performed.

End point values	EVP-6124, 2 mg	EVP-6124, 3 mg	Pbo-EVP-6124, 2 mg	Pbo-EVP-6124, 3 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	106	110	61	59
Units: celsius				
arithmetic mean (full range (min-max))	4 (-60 to 62)	6.9 (-2 to 62)	2.3 (-57 to 61)	-0.1 (-2 to 1)

### Statistical analyses

No statistical analyses for this end point

### Primary: Systolic Blood Pressure (Change from baseline)

End point title	Systolic Blood Pressure (Change from baseline) <sup>[38]</sup>
-----------------	--

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Days 28, 56, 84, 112, 140, and 182

Notes:

[38] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due to the premature termination of the studies, a full statistical analysis could not be performed.

End point values	EVP-6124, 2 mg	EVP-6124, 3 mg	Pbo-EVP-6124, 2 mg	Pbo-EVP-6124, 3 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	106	110	61	59
Units: mmHg				
arithmetic mean (full range (min-max))	-1 (-25 to 40)	-8.2 (-63 to 30)	-4.8 (-37 to 19)	-2.7 (-46 to 38)

### Statistical analyses

No statistical analyses for this end point

### Primary: Diastolic Blood Pressure (Change from baseline)

End point title	Diastolic Blood Pressure (Change from baseline) <sup>[39]</sup>
-----------------	---

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Days 28, 56, 84, 112, 140, and 182

Notes:

[39] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due to the premature termination of the studies, a full statistical analysis could not be performed.

End point values	EVP-6124, 2 mg	EVP-6124, 3 mg	Pbo-EVP-6124, 2 mg	Pbo-EVP-6124, 3 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	106	110	61	59
Units: mmHg				
arithmetic mean (full range (min-max))	-0.7 (-26 to 47)	-1.9 (-22 to 28)	0.7 (-20 to 19)	-3.1 (-22 to 30)

## Statistical analyses

No statistical analyses for this end point

### Primary: Heart Rate (Change from baseline)

End point title	Heart Rate (Change from baseline) <sup>[40]</sup>
-----------------	---

End point description:

End point type	Primary
----------------	---------

End point timeframe:

12-lead electrocardiogram (ECG): Days 28, 56, 112, 140, and 182

Notes:

[40] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due to the premature termination of the studies, a full statistical analysis could not be performed.

End point values	EVP-6124, 2 mg	EVP-6124, 3 mg	Pbo-EVP-6124, 2 mg	Pbo-EVP-6124, 3 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	106	110	61	59
Units: bpm				
arithmetic mean (full range (min-max))	0.8 (-22 to 19)	1.3 (-21 to 26)	-0.7 (-20 to 15)	1.4 (-18 to 17)

## Statistical analyses

No statistical analyses for this end point

### Primary: Respiratory Rate (Change from baseline)

End point title	Respiratory Rate (Change from baseline) <sup>[41]</sup>
-----------------	---

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Days 28, 56, 84, 112, 140, and 182

Notes:

[41] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due to the premature termination of the studies, a full statistical analysis could not be performed.

End point values	EVP-6124, 2 mg	EVP-6124, 3 mg	Pbo-EVP-6124, 2 mg	Pbo-EVP-6124, 3 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	106	110	61	59
Units: breaths/min				
arithmetic mean (full range (min-max))	0.7 (-6 to 8)	-0.1 (-7 to 6)	0.1 (-4 to 6)	-0.1 (-5 to 2)

## Statistical analyses

No statistical analyses for this end point

### Primary: Weight (Change from baseline)

End point title	Weight (Change from baseline) <sup>[42]</sup>
-----------------	---

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Days 28, 56, 84, 112, 140, and 182

Notes:

[42] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due to the premature termination of the studies, a full statistical analysis could not be performed.

End point values	EVP-6124, 2 mg	EVP-6124, 3 mg	Pbo-EVP-6124, 2 mg	Pbo-EVP-6124, 3 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	106	110	61	59
Units: kg				
arithmetic mean (full range (min-max))	8.1 (-11 to 101)	7.3 (-91 to 103)	7.7 (-3 to 107)	-0.7 (-18 to 8)

## Statistical analyses

No statistical analyses for this end point

### Primary: Columbia Suicide Severity Rating Scale (C-SSRS) (Change from baseline)

End point title	Columbia Suicide Severity Rating Scale (C-SSRS) (Change from baseline) <sup>[43]</sup>
-----------------	--

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Days 28, 56, 84, 112, 140, and 182

Notes:

[43] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due to the premature termination of the studies, a full statistical analysis could not be performed.

<b>End point values</b>	EVP-6124, 2 mg	EVP-6124, 3 mg	Pbo-EVP-6124, 2 mg	Pbo-EVP-6124, 3 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	106	110	61	59
Units: Subjects wishing to be dead	0	1	0	0

### Statistical analyses

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Adverse events observed at any time after the ICF is signed through the safety follow-up telephone contact (Day 189 or early termination, as applicable) will be recorded.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	17.1
--------------------	------

### Reporting groups

Reporting group title	EVP-6124, 2 mg
-----------------------	----------------

Reporting group description:

Previously treated with EVP-6124 will receive the same dose during this study as received in the previous study and subjects previously treated with placebo will be randomized to EVP-6124 2 or 3 mg daily (1:1 ratio).

Reporting group title	EVP-6124, 3 mg
-----------------------	----------------

Reporting group description:

Previously treated with EVP-6124 will receive the same dose during this study as received in the previous study and subjects previously treated with placebo will be randomized to EVP-6124 2 or 3 mg daily (1:1 ratio).

Reporting group title	Pbo-EVP-6124, 2 mg
-----------------------	--------------------

Reporting group description:

Previously treated with EVP-6124 will receive the same dose during this study as received in the previous study and subjects previously treated with placebo will be randomized to EVP-6124 2 or 3 mg daily (1:1 ratio).

Reporting group title	Pbo-EVP-6124, 3 mg
-----------------------	--------------------

Reporting group description:

Previously treated with EVP-6124 will receive the same dose during this study as received in the previous study and subjects previously treated with placebo will be randomized to EVP-6124 2 or 3 mg daily (1:1 ratio).

Serious adverse events	EVP-6124, 2 mg	EVP-6124, 3 mg	Pbo-EVP-6124, 2 mg
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 106 (3.77%)	7 / 110 (6.36%)	4 / 61 (6.56%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Gastric cancer recurrent			
subjects affected / exposed	1 / 106 (0.94%)	0 / 110 (0.00%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 7	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bladder cancer recurrent			



subjects affected / exposed	0 / 106 (0.00%)	0 / 110 (0.00%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 7	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ovarian cancer			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 7	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Femoral neck fracture			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 7	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 7	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Bradycardia			
subjects affected / exposed	1 / 106 (0.94%)	0 / 110 (0.00%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 7	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sick sinus syndrome			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 7	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myocardial infarction			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 7	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure			
subjects affected / exposed	0 / 106 (0.00%)	0 / 110 (0.00%)	1 / 61 (1.64%)
occurrences causally related to treatment / all	0 / 4	0 / 7	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Nervous system disorders			
Cerebral haemorrhage			
subjects affected / exposed	0 / 106 (0.00%)	0 / 110 (0.00%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 7	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dementia Alzheimer's type			
subjects affected / exposed	0 / 106 (0.00%)	0 / 110 (0.00%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 7	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Colitis ulcerative			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 7	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain			
subjects affected / exposed	1 / 106 (0.94%)	0 / 110 (0.00%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 7	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticular perforation			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 4	1 / 7	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mesenteric occlusion			
subjects affected / exposed	0 / 106 (0.00%)	0 / 110 (0.00%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 7	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	1 / 106 (0.94%)	0 / 110 (0.00%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 7	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Agitation			

subjects affected / exposed	0 / 106 (0.00%)	0 / 110 (0.00%)	1 / 61 (1.64%)
occurrences causally related to treatment / all	0 / 4	0 / 7	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Delirium			
subjects affected / exposed	0 / 106 (0.00%)	0 / 110 (0.00%)	1 / 61 (1.64%)
occurrences causally related to treatment / all	0 / 4	0 / 7	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Renal colic			
subjects affected / exposed	1 / 106 (0.94%)	0 / 110 (0.00%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 7	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Diverticulitis			
subjects affected / exposed	0 / 106 (0.00%)	0 / 110 (0.00%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 7	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 106 (0.00%)	0 / 110 (0.00%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 7	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hyponatraemia			
subjects affected / exposed	0 / 106 (0.00%)	0 / 110 (0.00%)	1 / 61 (1.64%)
occurrences causally related to treatment / all	0 / 4	0 / 7	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dehydration			
subjects affected / exposed	0 / 106 (0.00%)	0 / 110 (0.00%)	1 / 61 (1.64%)
occurrences causally related to treatment / all	0 / 4	0 / 7	1 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Serious adverse events</b>	Pbo-EVP-6124, 3 mg		
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 59 (6.78%)		
number of deaths (all causes)	2		

number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Gastric cancer recurrent			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Bladder cancer recurrent			
subjects affected / exposed	1 / 59 (1.69%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Ovarian cancer			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Femoral neck fracture			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Bradycardia			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Sick sinus syndrome			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Acute myocardial infarction			

subjects affected / exposed	0 / 59 (0.00%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Cardiac failure			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Cerebral haemorrhage			
subjects affected / exposed	1 / 59 (1.69%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 1		
Dementia Alzheimer's type			
subjects affected / exposed	1 / 59 (1.69%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 1		
Gastrointestinal disorders			
Colitis ulcerative			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Abdominal pain			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Diverticular perforation			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Mesenteric occlusion			
subjects affected / exposed	1 / 59 (1.69%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 1		
Respiratory, thoracic and mediastinal			

disorders			
Asthma			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
Agitation			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Delirium			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Renal colic			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Diverticulitis			
subjects affected / exposed	1 / 59 (1.69%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Sepsis			
subjects affected / exposed	1 / 59 (1.69%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 1		
Metabolism and nutrition disorders			
Hyponatraemia			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Dehydration			

subjects affected / exposed	0 / 59 (0.00%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 1 %

<b>Non-serious adverse events</b>	EVP-6124, 2 mg	EVP-6124, 3 mg	Pbo-EVP-6124, 2 mg
Total subjects affected by non-serious adverse events			
subjects affected / exposed	42 / 106 (39.62%)	42 / 110 (38.18%)	23 / 61 (37.70%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Bladder cancer recurrent			
subjects affected / exposed	0 / 106 (0.00%)	0 / 110 (0.00%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Gastric cancer recurrent			
subjects affected / exposed	1 / 106 (0.94%)	0 / 110 (0.00%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Ovarian cancer			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Thyroid neoplasm			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Hypotension			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
General disorders and administration site conditions			
Gait disturbance			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	1 / 61 (1.64%)
occurrences (all)	42	42	23
Oedema peripheral			

subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	1 / 61 (1.64%)
occurrences (all)	42	42	23
Asthenia			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Fatigue			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Irritability			
subjects affected / exposed	1 / 106 (0.94%)	0 / 110 (0.00%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Non-cardiac chest pain			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Pain			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Rhinorrhoea			
subjects affected / exposed	2 / 106 (1.89%)	0 / 110 (0.00%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Asthma			
subjects affected / exposed	1 / 106 (0.94%)	0 / 110 (0.00%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Psychiatric disorders			
Agitation			
subjects affected / exposed	1 / 106 (0.94%)	1 / 110 (0.91%)	1 / 61 (1.64%)
occurrences (all)	42	42	23
Confusional state			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	1 / 61 (1.64%)
occurrences (all)	42	42	23
Delirium			



subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 42	0 / 110 (0.00%) 42	2 / 61 (3.28%) 23
Hallucination subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 42	1 / 110 (0.91%) 42	0 / 61 (0.00%) 23
Insomnia subjects affected / exposed occurrences (all)	2 / 106 (1.89%) 42	0 / 110 (0.00%) 42	0 / 61 (0.00%) 23
Abnormal behaviour subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 42	0 / 110 (0.00%) 42	0 / 61 (0.00%) 23
Anxiety subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 42	1 / 110 (0.91%) 42	0 / 61 (0.00%) 23
Depression subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 42	1 / 110 (0.91%) 42	0 / 61 (0.00%) 23
Depressive symptom subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 42	0 / 110 (0.00%) 42	0 / 61 (0.00%) 23
Hypersexuality subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 42	0 / 110 (0.00%) 42	0 / 61 (0.00%) 23
Panic attack subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 42	1 / 110 (0.91%) 42	0 / 61 (0.00%) 23
Investigations Specific gravity urine increased subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 42	1 / 110 (0.91%) 42	1 / 61 (1.64%) 23
Blood pressure decreased subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 42	0 / 110 (0.00%) 42	0 / 61 (0.00%) 23
Blood urine present subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 42	0 / 110 (0.00%) 42	0 / 61 (0.00%) 23

Electrocardiogram QT prolonged subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 42	0 / 110 (0.00%) 42	0 / 61 (0.00%) 23
Eosinophil count increased subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 42	0 / 110 (0.00%) 42	0 / 61 (0.00%) 23
Heart rate irregular subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 42	0 / 110 (0.00%) 42	0 / 61 (0.00%) 23
Protein urine subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 42	0 / 110 (0.00%) 42	0 / 61 (0.00%) 23
Specific gravity urine abnormal subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 42	0 / 110 (0.00%) 42	0 / 61 (0.00%) 23
Weight decreased subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 42	0 / 110 (0.00%) 42	0 / 61 (0.00%) 23
Weight increased subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 42	0 / 110 (0.00%) 42	0 / 61 (0.00%) 23
White blood cells urine subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 42	0 / 110 (0.00%) 42	0 / 61 (0.00%) 23
Injury, poisoning and procedural complications			
Fall subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 42	0 / 110 (0.00%) 42	2 / 61 (3.28%) 23
Laceration subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 42	1 / 110 (0.91%) 42	0 / 61 (0.00%) 23
Contusion subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 42	0 / 110 (0.00%) 42	1 / 61 (1.64%) 23
Ankle fracture			

subjects affected / exposed	0 / 106 (0.00%)	0 / 110 (0.00%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Arthropod bite			
subjects affected / exposed	1 / 106 (0.94%)	0 / 110 (0.00%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Confusion postoperative			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Excoriation			
subjects affected / exposed	0 / 106 (0.00%)	0 / 110 (0.00%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Femoral neck fracture			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Procedural pain			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Spinal fracture			
subjects affected / exposed	0 / 106 (0.00%)	0 / 110 (0.00%)	1 / 61 (1.64%)
occurrences (all)	42	42	23
Thoracic vertebral fracture			
subjects affected / exposed	0 / 106 (0.00%)	0 / 110 (0.00%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Cardiac disorders			
Bradycardia			
subjects affected / exposed	1 / 106 (0.94%)	0 / 110 (0.00%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Acute myocardial infarction			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Angina pectoris			
subjects affected / exposed	0 / 106 (0.00%)	0 / 110 (0.00%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Bradyarrhythmia			
subjects affected / exposed	1 / 106 (0.94%)	0 / 110 (0.00%)	0 / 61 (0.00%)
occurrences (all)	42	42	23

Bundle branch block left subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 42	0 / 110 (0.00%) 42	0 / 61 (0.00%) 23
Cardiac failure subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 42	0 / 110 (0.00%) 42	1 / 61 (1.64%) 23
Palpitations subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 42	0 / 110 (0.00%) 42	1 / 61 (1.64%) 23
Sick sinus syndrome subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 42	1 / 110 (0.91%) 42	0 / 61 (0.00%) 23
Nervous system disorders			
Dizziness subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 42	1 / 110 (0.91%) 42	2 / 61 (3.28%) 23
Syncope subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 42	2 / 110 (1.82%) 42	0 / 61 (0.00%) 23
Cognitive disorder subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 42	1 / 110 (0.91%) 42	0 / 61 (0.00%) 23
Headache subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 42	0 / 110 (0.00%) 42	1 / 61 (1.64%) 23
Altered state of consciousness subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 42	0 / 110 (0.00%) 42	0 / 61 (0.00%) 23
Cerebral haemorrhage subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 42	0 / 110 (0.00%) 42	0 / 61 (0.00%) 23
Dementia subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 42	0 / 110 (0.00%) 42	1 / 61 (1.64%) 23
Dementia Alzheimer's type			

subjects affected / exposed	0 / 106 (0.00%)	0 / 110 (0.00%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Migraine			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Neuralgia			
subjects affected / exposed	1 / 106 (0.94%)	0 / 110 (0.00%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Parkinsonism			
subjects affected / exposed	0 / 106 (0.00%)	0 / 110 (0.00%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Postural reflex impairment			
subjects affected / exposed	0 / 106 (0.00%)	0 / 110 (0.00%)	1 / 61 (1.64%)
occurrences (all)	42	42	23
Presyncope			
subjects affected / exposed	0 / 106 (0.00%)	0 / 110 (0.00%)	1 / 61 (1.64%)
occurrences (all)	42	42	23
Psychomotor skills impaired			
subjects affected / exposed	1 / 106 (0.94%)	0 / 110 (0.00%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 106 (0.00%)	0 / 110 (0.00%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Eosinophilia			
subjects affected / exposed	0 / 106 (0.00%)	0 / 110 (0.00%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Lymphopenia			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Neutrophilia			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Eye disorders			
Cataract			

subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Conjunctivitis			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Retinal detachment			
subjects affected / exposed	1 / 106 (0.94%)	0 / 110 (0.00%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Gastrointestinal disorders			
Constipation			
subjects affected / exposed	9 / 106 (8.49%)	12 / 110 (10.91%)	11 / 61 (18.03%)
occurrences (all)	42	42	23
Diarrhoea			
subjects affected / exposed	9 / 106 (8.49%)	7 / 110 (6.36%)	4 / 61 (6.56%)
occurrences (all)	42	42	23
Nausea			
subjects affected / exposed	5 / 106 (4.72%)	5 / 110 (4.55%)	4 / 61 (6.56%)
occurrences (all)	42	42	23
Abdominal pain			
subjects affected / exposed	3 / 106 (2.83%)	1 / 110 (0.91%)	3 / 61 (4.92%)
occurrences (all)	42	42	23
Vomiting			
subjects affected / exposed	3 / 106 (2.83%)	2 / 110 (1.82%)	1 / 61 (1.64%)
occurrences (all)	42	42	23
Faecal incontinence			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	1 / 61 (1.64%)
occurrences (all)	42	42	23
Faeces hard			
subjects affected / exposed	1 / 106 (0.94%)	1 / 110 (0.91%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Haematochezia			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	1 / 61 (1.64%)
occurrences (all)	42	42	23
Rectal tenesmus			
subjects affected / exposed	1 / 106 (0.94%)	0 / 110 (0.00%)	1 / 61 (1.64%)
occurrences (all)	42	42	23

Toothache			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Colitis ulcerative			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Diverticular perforation			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Dyschezia			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Gastrointestinal motility disorder			
subjects affected / exposed	1 / 106 (0.94%)	0 / 110 (0.00%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Haemorrhoidal haemorrhage			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Mesenteric occlusion			
subjects affected / exposed	0 / 106 (0.00%)	0 / 110 (0.00%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Oesophagitis			
subjects affected / exposed	0 / 106 (0.00%)	0 / 110 (0.00%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Periodontal disease			
subjects affected / exposed	0 / 106 (0.00%)	0 / 110 (0.00%)	1 / 61 (1.64%)
occurrences (all)	42	42	23
Salivary gland mass			
subjects affected / exposed	0 / 106 (0.00%)	0 / 110 (0.00%)	1 / 61 (1.64%)
occurrences (all)	42	42	23
Skin and subcutaneous tissue disorders			
Rash			
subjects affected / exposed	1 / 106 (0.94%)	1 / 110 (0.91%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Psoriasis			

subjects affected / exposed	2 / 106 (1.89%)	0 / 110 (0.00%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Dermatitis contact			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Pruritus			
subjects affected / exposed	1 / 106 (0.94%)	0 / 110 (0.00%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Rash pruritic			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Skin lesion			
subjects affected / exposed	0 / 106 (0.00%)	0 / 110 (0.00%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Renal and urinary disorders			
Haematuria			
subjects affected / exposed	1 / 106 (0.94%)	0 / 110 (0.00%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Urinary incontinence			
subjects affected / exposed	1 / 106 (0.94%)	0 / 110 (0.00%)	1 / 61 (1.64%)
occurrences (all)	42	42	23
Enuresis			
subjects affected / exposed	1 / 106 (0.94%)	0 / 110 (0.00%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Glycosuria			
subjects affected / exposed	0 / 106 (0.00%)	0 / 110 (0.00%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Proteinuria			
subjects affected / exposed	0 / 106 (0.00%)	0 / 110 (0.00%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Renal colic			
subjects affected / exposed	1 / 106 (0.94%)	0 / 110 (0.00%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Renal failure			
subjects affected / exposed	0 / 106 (0.00%)	0 / 110 (0.00%)	1 / 61 (1.64%)
occurrences (all)	42	42	23



Renal failure acute subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 42	0 / 110 (0.00%) 42	1 / 61 (1.64%) 23
Renal impairment subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 42	0 / 110 (0.00%) 42	0 / 61 (0.00%) 23
Urinary retention subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 42	0 / 110 (0.00%) 42	1 / 61 (1.64%) 23
Endocrine disorders Inappropriate antidiuretic hormone secretion subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 42	0 / 110 (0.00%) 42	1 / 61 (1.64%) 23
Musculoskeletal and connective tissue disorders			
Back pain subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 42	1 / 110 (0.91%) 42	3 / 61 (4.92%) 23
Arthralgia subjects affected / exposed occurrences (all)	3 / 106 (2.83%) 42	1 / 110 (0.91%) 42	1 / 61 (1.64%) 23
Musculoskeletal stiffness subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 42	1 / 110 (0.91%) 42	1 / 61 (1.64%) 23
Arthritis subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 42	0 / 110 (0.00%) 42	1 / 61 (1.64%) 23
Costochondritis subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 42	1 / 110 (0.91%) 42	0 / 61 (0.00%) 23
Foot deformity subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 42	0 / 110 (0.00%) 42	0 / 61 (0.00%) 23
Osteoarthritis subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 42	1 / 110 (0.91%) 42	0 / 61 (0.00%) 23
Pain in extremity			

subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 42	1 / 110 (0.91%) 42	0 / 61 (0.00%) 23
Rotator cuff syndrome subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 42	0 / 110 (0.00%) 42	0 / 61 (0.00%) 23
Temporomandibular joint syndrome subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 42	0 / 110 (0.00%) 42	0 / 61 (0.00%) 23
Infections and infestations			
Urinary tract infection subjects affected / exposed occurrences (all)	2 / 106 (1.89%) 42	2 / 110 (1.82%) 42	1 / 61 (1.64%) 23
Upper respiratory tract infection subjects affected / exposed occurrences (all)	2 / 106 (1.89%) 42	1 / 110 (0.91%) 42	0 / 61 (0.00%) 23
Nasopharyngitis subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 42	3 / 110 (2.73%) 42	0 / 61 (0.00%) 23
Bacteriuria subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 42	0 / 110 (0.00%) 42	0 / 61 (0.00%) 23
Cellulitis subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 42	0 / 110 (0.00%) 42	0 / 61 (0.00%) 23
Diverticulitis subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 42	0 / 110 (0.00%) 42	0 / 61 (0.00%) 23
Herpes zoster subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 42	0 / 110 (0.00%) 42	0 / 61 (0.00%) 23
Pharyngitis subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 42	1 / 110 (0.91%) 42	0 / 61 (0.00%) 23
Pneumonia subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 42	1 / 110 (0.91%) 42	0 / 61 (0.00%) 23

Sepsis			
subjects affected / exposed	0 / 106 (0.00%)	0 / 110 (0.00%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Staphylococcal infection			
subjects affected / exposed	1 / 106 (0.94%)	0 / 110 (0.00%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Tonsillitis			
subjects affected / exposed	0 / 106 (0.00%)	0 / 110 (0.00%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Vulvovaginal candidiasis			
subjects affected / exposed	0 / 106 (0.00%)	0 / 110 (0.00%)	1 / 61 (1.64%)
occurrences (all)	42	42	23
Wound sepsis			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Metabolism and nutrition disorders			
Hyperglycaemia			
subjects affected / exposed	1 / 106 (0.94%)	1 / 110 (0.91%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Hypokalaemia			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	1 / 61 (1.64%)
occurrences (all)	42	42	23
Dehydration			
subjects affected / exposed	0 / 106 (0.00%)	0 / 110 (0.00%)	1 / 61 (1.64%)
occurrences (all)	42	42	23
Gout			
subjects affected / exposed	1 / 106 (0.94%)	0 / 110 (0.00%)	0 / 61 (0.00%)
occurrences (all)	42	42	23
Hypernatraemia			
subjects affected / exposed	0 / 106 (0.00%)	0 / 110 (0.00%)	1 / 61 (1.64%)
occurrences (all)	42	42	23
Hyponatraemia			
subjects affected / exposed	0 / 106 (0.00%)	0 / 110 (0.00%)	1 / 61 (1.64%)
occurrences (all)	42	42	23
Type 2 diabetes mellitus			

subjects affected / exposed	1 / 106 (0.94%)	0 / 110 (0.00%)	0 / 61 (0.00%)
occurrences (all)	42	42	23

<b>Non-serious adverse events</b>	Pbo-EVP-6124, 3 mg		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	30 / 59 (50.85%)		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Bladder cancer recurrent			
subjects affected / exposed	1 / 59 (1.69%)		
occurrences (all)	30		
Gastric cancer recurrent			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Ovarian cancer			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Thyroid neoplasm			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Hypotension			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
General disorders and administration site conditions			
Gait disturbance			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Oedema peripheral			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Asthenia			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		

<p>Fatigue</p> <p>subjects affected / exposed</p> <p>0 / 59 (0.00%)</p> <p>occurrences (all)</p> <p>30</p>			
<p>Irritability</p> <p>subjects affected / exposed</p> <p>0 / 59 (0.00%)</p> <p>occurrences (all)</p> <p>30</p>			
<p>Non-cardiac chest pain</p> <p>subjects affected / exposed</p> <p>0 / 59 (0.00%)</p> <p>occurrences (all)</p> <p>30</p>			
<p>Pain</p> <p>subjects affected / exposed</p> <p>0 / 59 (0.00%)</p> <p>occurrences (all)</p> <p>30</p>			
<p>Respiratory, thoracic and mediastinal disorders</p> <p>Cough</p> <p>subjects affected / exposed</p> <p>1 / 59 (1.69%)</p> <p>occurrences (all)</p> <p>30</p> <p>Rhinorrhoea</p> <p>subjects affected / exposed</p> <p>0 / 59 (0.00%)</p> <p>occurrences (all)</p> <p>30</p> <p>Asthma</p> <p>subjects affected / exposed</p> <p>0 / 59 (0.00%)</p> <p>occurrences (all)</p> <p>30</p>			
<p>Psychiatric disorders</p> <p>Agitation</p> <p>subjects affected / exposed</p> <p>0 / 59 (0.00%)</p> <p>occurrences (all)</p> <p>30</p> <p>Confusional state</p> <p>subjects affected / exposed</p> <p>0 / 59 (0.00%)</p> <p>occurrences (all)</p> <p>30</p> <p>Delirium</p> <p>subjects affected / exposed</p> <p>0 / 59 (0.00%)</p> <p>occurrences (all)</p> <p>30</p> <p>Hallucination</p> <p>subjects affected / exposed</p> <p>0 / 59 (0.00%)</p> <p>occurrences (all)</p> <p>30</p> <p>Insomnia</p>			

subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Abnormal behaviour			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Anxiety			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Depression			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Depressive symptom			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Hypersexuality			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Panic attack			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Investigations			
Specific gravity urine increased			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Blood pressure decreased			
subjects affected / exposed	1 / 59 (1.69%)		
occurrences (all)	30		
Blood urine present			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Electrocardiogram QT prolonged			
subjects affected / exposed	1 / 59 (1.69%)		
occurrences (all)	30		
Eosinophil count increased			
subjects affected / exposed	1 / 59 (1.69%)		
occurrences (all)	30		

Heart rate irregular subjects affected / exposed occurrences (all)	1 / 59 (1.69%) 30		
Protein urine subjects affected / exposed occurrences (all)	1 / 59 (1.69%) 30		
Specific gravity urine abnormal subjects affected / exposed occurrences (all)	1 / 59 (1.69%) 30		
Weight decreased subjects affected / exposed occurrences (all)	0 / 59 (0.00%) 30		
Weight increased subjects affected / exposed occurrences (all)	0 / 59 (0.00%) 30		
White blood cells urine subjects affected / exposed occurrences (all)	1 / 59 (1.69%) 30		
Injury, poisoning and procedural complications			
Fall subjects affected / exposed occurrences (all)	3 / 59 (5.08%) 30		
Laceration subjects affected / exposed occurrences (all)	1 / 59 (1.69%) 30		
Contusion subjects affected / exposed occurrences (all)	0 / 59 (0.00%) 30		
Ankle fracture subjects affected / exposed occurrences (all)	1 / 59 (1.69%) 30		
Arthropod bite subjects affected / exposed occurrences (all)	0 / 59 (0.00%) 30		
Confusion postoperative			

subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Excoriation			
subjects affected / exposed	1 / 59 (1.69%)		
occurrences (all)	30		
Femoral neck fracture			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Procedural pain			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Spinal fracture			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Thoracic vertebral fracture			
subjects affected / exposed	1 / 59 (1.69%)		
occurrences (all)	30		
Cardiac disorders			
Bradycardia			
subjects affected / exposed	1 / 59 (1.69%)		
occurrences (all)	30		
Acute myocardial infarction			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Angina pectoris			
subjects affected / exposed	1 / 59 (1.69%)		
occurrences (all)	30		
Bradyarrhythmia			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Bundle branch block left			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Cardiac failure			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		



Palpitations			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Sick sinus syndrome			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Syncope			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Cognitive disorder			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Headache			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Altered state of consciousness			
subjects affected / exposed	1 / 59 (1.69%)		
occurrences (all)	30		
Cerebral haemorrhage			
subjects affected / exposed	1 / 59 (1.69%)		
occurrences (all)	30		
Dementia			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Dementia Alzheimer's type			
subjects affected / exposed	1 / 59 (1.69%)		
occurrences (all)	30		
Migraine			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Neuralgia			

subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Parkinsonism			
subjects affected / exposed	1 / 59 (1.69%)		
occurrences (all)	30		
Postural reflex impairment			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Presyncope			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Psychomotor skills impaired			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 59 (1.69%)		
occurrences (all)	30		
Eosinophilia			
subjects affected / exposed	1 / 59 (1.69%)		
occurrences (all)	30		
Lymphopenia			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Neutrophilia			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Eye disorders			
Cataract			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Conjunctivitis			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Retinal detachment			

subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Gastrointestinal disorders			
Constipation			
subjects affected / exposed	9 / 59 (15.25%)		
occurrences (all)	30		
Diarrhoea			
subjects affected / exposed	3 / 59 (5.08%)		
occurrences (all)	30		
Nausea			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Abdominal pain			
subjects affected / exposed	2 / 59 (3.39%)		
occurrences (all)	30		
Vomiting			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Faecal incontinence			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Faeces hard			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Haematochezia			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Rectal tenesmus			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Toothache			
subjects affected / exposed	1 / 59 (1.69%)		
occurrences (all)	30		
Colitis ulcerative			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		

Diverticular perforation			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Dyschezia			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Gastrointestinal motility disorder			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Haemorrhoidal haemorrhage			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Mesenteric occlusion			
subjects affected / exposed	1 / 59 (1.69%)		
occurrences (all)	30		
Oesophagitis			
subjects affected / exposed	1 / 59 (1.69%)		
occurrences (all)	30		
Periodontal disease			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Salivary gland mass			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Skin and subcutaneous tissue disorders			
Rash			
subjects affected / exposed	1 / 59 (1.69%)		
occurrences (all)	30		
Psoriasis			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Dermatitis contact			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Pruritus			

subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Rash pruritic			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Skin lesion			
subjects affected / exposed	1 / 59 (1.69%)		
occurrences (all)	30		
Renal and urinary disorders			
Haematuria			
subjects affected / exposed	2 / 59 (3.39%)		
occurrences (all)	30		
Urinary incontinence			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Enuresis			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Glycosuria			
subjects affected / exposed	1 / 59 (1.69%)		
occurrences (all)	30		
Proteinuria			
subjects affected / exposed	1 / 59 (1.69%)		
occurrences (all)	30		
Renal colic			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Renal failure			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Renal failure acute			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Renal impairment			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		

Urinary retention subjects affected / exposed occurrences (all)	0 / 59 (0.00%) 30		
Endocrine disorders Inappropriate antidiuretic hormone secretion subjects affected / exposed occurrences (all)	0 / 59 (0.00%) 30		
Musculoskeletal and connective tissue disorders Back pain subjects affected / exposed occurrences (all)  Arthralgia subjects affected / exposed occurrences (all)  Musculoskeletal stiffness subjects affected / exposed occurrences (all)  Arthritis subjects affected / exposed occurrences (all)  Costochondritis subjects affected / exposed occurrences (all)  Foot deformity subjects affected / exposed occurrences (all)  Osteoarthritis subjects affected / exposed occurrences (all)  Pain in extremity subjects affected / exposed occurrences (all)  Rotator cuff syndrome subjects affected / exposed occurrences (all)  Temporomandibular joint syndrome	1 / 59 (1.69%) 30  0 / 59 (0.00%) 30  0 / 59 (0.00%) 30  0 / 59 (0.00%) 30  0 / 59 (0.00%) 30  1 / 59 (1.69%) 30  0 / 59 (0.00%) 30  0 / 59 (0.00%) 30  0 / 59 (0.00%) 30		

subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Infections and infestations			
Urinary tract infection			
subjects affected / exposed	1 / 59 (1.69%)		
occurrences (all)	30		
Upper respiratory tract infection			
subjects affected / exposed	2 / 59 (3.39%)		
occurrences (all)	30		
Nasopharyngitis			
subjects affected / exposed	1 / 59 (1.69%)		
occurrences (all)	30		
Bacteriuria			
subjects affected / exposed	1 / 59 (1.69%)		
occurrences (all)	30		
Cellulitis			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Diverticulitis			
subjects affected / exposed	1 / 59 (1.69%)		
occurrences (all)	30		
Herpes zoster			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Pharyngitis			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Pneumonia			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Sepsis			
subjects affected / exposed	1 / 59 (1.69%)		
occurrences (all)	30		
Staphylococcal infection			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		

Tonsillitis			
subjects affected / exposed	1 / 59 (1.69%)		
occurrences (all)	30		
Vulvovaginal candidiasis			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Wound sepsis			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Metabolism and nutrition disorders			
Hyperglycaemia			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Hypokalaemia			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Dehydration			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Gout			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Hypernatraemia			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Hyponatraemia			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		
Type 2 diabetes mellitus			
subjects affected / exposed	0 / 59 (0.00%)		
occurrences (all)	30		



## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? Yes

Date	Interruption	Restart date
23 December 2015	The Phase 3 Alzheimer's disease studies (EVP-6124-024, EVP-6124-025 and EVP-6124-026) were placed on complete clinical hold by the FDA due to potential gastrointestinal safety concern(s) around September 1st, 2015. Subsequent to this time, they were terminated to analyze the available data around January 1st, 2016.	-

Notes:

### Limitations and caveats

None reported